CTOR - Citius Oncology Quarterly Revenue Growth

Corporate company logo of citiusonc.com (CTOR)

The success of Citius Oncology, Inc. (CTOR) is based on the pace of bringing its lymphoma therapy to market following its spin-off from the parent structure. Growth potential is driven by the creation of unique molecules for global distribution. This quarterly revenue chart helps assess the speed of income expansion, where the 0.00 metric determines this level. The company's environmental policy is limited to standard laboratory safety controls.

Citius Oncology, Inc (CTOR) - Quarterly Revenue Growth from 08/14/2024 to 11/20/2026

Analytical breakdowns for Citius Oncology Inc. (CTOR)

- cash and cash flow metrics:
Basic company analysis:CTOR - Citius Oncology
Flagship merchandise of Citius Oncology

This metric measures the rate of revenue change between two consecutive quarters, identifying fundamental momentum prior to a market revaluation of the asset. Analyzing quarterly sales dynamics allows for the determination of the exact moment a company transitions toward scaling its business. However, for Citius Oncology, Inc. (CTOR), such data remains limited. The absence of commercial products renders cash flows unpredictable, turning the metric into an indicator of the investment stage of development.

Direct competitors

BeiGene Oncology - Quarterly Revenue Growth|HALO: Revenue Growth QoQ|Revolution Medicines Corp (RVMD) - Revenue Growth QoQ|Quarterly Revenue Growth Rate Ascentage Pharma Group International (AAPG)|Revenue Growth QoQ CG Oncology, Inc.|Quarterly Revenue Growth Rate UroGen Pharma Corp URGN|Quarterly Revenue Growth BCAX|Personalis, Inc. - Sales Growth QoQ|Erasca - Quarterly Sales Growth|Quarterly Revenue Increase DCTH|YMAB: Quarterly Sales Growth|Quarterly Revenue Growth Rate Aura Corp|CADL: Quarterly Revenue Growth|ARAY - Quarterly Sales Growth Rate|SLS (SELLAS Life Sciences Group, Inc.) - Quarterly Revenue Growth|ACTU: Quarterly Revenue Increase|Revenue Growth QoQ TuHURA (HURA)|TARA - Quarterly Revenue Growth Rate|Quarterly Revenue Growth FATE (Fate Therapeutics Inc)|Aadi Bioscience Inc (WHWK) - Quarterly Revenue Growth Rate|TScan - Quarterly Revenue Growth|Champions Oncology, Inc. (CSBR) - Quarterly Sales Growth|XBIT (XBiotech Inc.) - Quarterly Sales Growth|CEL-SCI Corporation (CVM) - Quarterly Revenue Growth|Revenue Growth QoQ OS Therapies|RADX: Quarterly Revenue Increase|Revenue Growth QoQ artivabio.com (ARTV)|Quarterly Sales Growth Rate Adlai Nortye|Quarterly Revenue Growth VERU (Veru Corporation)|Sales Change QoQ TPST (Tempest Tx)|XLO: Quarterly Sales Growth|renovarobio.com (RENB) - Quarterly Sales Growth|Mural Bio (MURA) - Revenue Growth QoQ|Kairos Pharma Inc (KAPA) - Quarterly Revenue Growth|Quarterly Sales Growth OKUR|CytoMed Therapeutics (GDTC) - Quarterly Sales Growth Rate|Quarterly Sales Growth CRIS (Curis Inc.)|Quarterly Revenue Growth Apollomics Inc. (APLM)|Revenue Growth QoQ Tharimmune Corp THAR|Advanced Biomed Corp - Revenue Growth QoQ|GNPX: Quarterly Sales Growth|Calidi Biotherapeutics, Inc. (CLDI) - Quarterly Sales Growth|SBFM: Quarterly Revenue Growth|Quarterly Sales Growth Xenetic Biosciences Inc.|Revenue Growth QoQ Salarius Pharmaceuticals Inc|PPBT: Quarterly Revenue Increase|Quarterly Revenue Growth AONC|BGNE (BeOne Medicines) - Quarterly Revenue Increase|Checkpoint Therapeutics, Inc - Quarterly Sales Growth|elevationoncology.com (ELEV) - Quarterly Revenue Growth Rate|iCAD Inc. - Quarterly Revenue Growth|Quarterly Revenue Growth Rate Ikena Oncology|NTBL: Quarterly Revenue Growth|Quarterly Revenue Growth Rate Viracta (VIRX)|MOR (MorphoSys AG) - Quarterly Revenue Growth|NAYA: Quarterly Revenue Increase|Revenue Growth QoQ Ascentage Pharma Group Ltd (AAPGV)